IVBXF
Innovent Biologics Inc$10.65 −0.90 (−7.78%)
Oct 26 4:00 PM ET · prev $11.55
1 year
−9.0%
from $11.70 · Oct 28
30 days
−20.3%
from $13.36
52-week range
$9.10–15.01
−29% from high · low Jun 8
Avg volume 20D
2.8K
Oct 19 spike 14.9K
Short interest
13.0K
−93.3%
Days to cover
2.1
at average volume
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E Mar 30 Trial readout: Results Pending: IBI310 (Phase 3) — Completed 89d ago
- X Sep 30 Short interest falls 81.2% to 194.5K
- E Oct 12 Trial readout: T-90d Trial Readout: IBI302 (Phase 2)
- E Oct 12 Trial readout: T-90d Trial Readout: IBI362 (Phase 3)
- X Oct 15 Short interest falls 93.3% to 13.0K
- E Oct 19 Trial readout: T-90d Trial Readout: IBI362 (Phase 3)
- E Oct 23 Trial readout: T-90d Trial Readout: IBI302 (Phase 2)
- E Oct 26 Trial readout: T-90d Trial Readout: IBI302 (Phase 2)
Signal stack
Where each data set points today.
- Short sellersCOVERING
Short interest −93.3% to 13.0K shares. 2.1 days to cover.
- TrendDOWNTREND
15% below its 50-day average.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 25, 2026
Trial readout
T-90d Trial Readout: IBI302 (Phase 2)
Trial: A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME） Sponsor: Innovent Biologics Technology…
Oct 23, 2026
Trial readout
T-90d Trial Readout: IBI302 (Phase 2)
Trial: A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME） Sponsor: Innovent Biologics Technology…
Oct 18, 2026
Trial readout
T-90d Trial Readout: IBI362 (Phase 3)
Trial: A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease…
Oct 12, 2026
Trial readout
T-90d Trial Readout: IBI302 (Phase 2)
Trial: A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME） Sponsor: Innovent Biologics Technology…
Oct 12, 2026
Trial readout
T-90d Trial Readout: IBI362 (Phase 3)
Trial: A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease…
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 202613,000
shares short
-93.3%
vs prior settlement
2.1
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 25, 2026 Clinical trial readout
T-90d Trial Readout: IBI302 (Phase 2)
Trial: A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（